Objective To investigate the expression level of heat shock protein 90 alpha (HSP90α) in human hepato-cellular carcinoma cell (HCC) lines with different metastatic potential and in the serum of hepatitis B virus (HBV) related HCC patients. Method Serum samples of 60 cases of liver disease patients infected by HBV and 12 cases of healthy sub-jects during same period were collected, in which the expression level of HSP90αin human HCC cell lines with different metastatic potential were detected by Western blot, and that in serum of HBV related liver cancer patients, benign liver disease patients and healthy subjects were detected by ELISA. The relationship between the expression level of HSP90αand the clinicopathological features of patients with HBV related HCC were analyzed statistically. Result In human HCC cell line (MHCC97H) with high metastatic potential, the expression of HSP90αwas significantly higher than those with no metastatic potential (HepG2), and the difference was statistically significant (t=13.375, P=0.001); patients with liver cancer and benign liver disease had significantly higher expression level of serum HSP90αcompared with healthy subjects, with statistically significant difference observed (F=11.357, P=0.002; F=9.633, P=0.005); while liver cancer group and benign liver disease group were similar in regard of serum HSP90αlevel (F=0.859, P=0.983);the expression level of HSP90αin serum of 42 liver cancer patients with chronic HBV infection was related to gender, in which, higher expression of serum HSP90αwas observed in female patients compared with male patients, and the difference was statisti-cally significant (F=4.729, P=0.039), but there was no significant relevance among age, positive HBeAg, AFP concentra-tion, HBV DNA and clinical stages (P>0.05). Conclusion HSP90α can be a new target for anticancer therapy, which may provide a theoretical basis for the early diagnosis of liver disease, the invasion and metastasis of HCC, the prognosis evaluation and the scientific treatment.%目的 探讨热休克蛋白90α(HSP90α)在不同转移潜能人肝癌细胞株及乙型肝炎病毒(HBV)相关性肝细胞癌患者血清中的表达水平.方法 收集HBV感染肝病患者60例和同期体检的健康受试者12例的血清样本,采用Western blot技术检测不同转移潜能人肝癌细胞株中HSP90α的表达水平,采用ELISA技术检测HBV相关性肝癌患者、良性肝病患者、健康受试者血清中HSP90α的表达水平,采用统计学方法分析HSP90α的表达水平与HBV相关性肝细胞癌患者临床病理特征的关系.结果 高转移潜能人肝癌细胞株MHCC97H细胞中HSP90α的表达水平明显高于无转移潜能人肝癌细胞株HepG2细胞,差异有统计学意义(t=13.375,P=0.001);肝癌组与良性肝病组患者血清中HSP90α的表达水平均明显高于健康受试者,差异有统计学意义(F=11.357,P=0.002;F=9.633,P=0.005),但肝癌组与良性肝病组患者血清中HSP90α的表达水平比较,差异无统计学意义(F=0.859,P=0.983);42例伴HBV慢性感染肝癌患者血清中HSP90α的表达水平与性别有关,其中,女性患者血清中HSP90α的表达水平高于男性患者,差异有统计学意义(F=4.729,P=0.039),但患者年龄、HBeAg是否为阳性、甲胎蛋白(AFP)浓度、HBV DNA及临床分期之间比较,差异无统计学意义(P﹥0.05).结论 HSP90α可成为抗癌治疗的新靶点,并为肝病的早期诊断、肝癌的侵袭转移、预后评估及科学治疗提供理论依据.
展开▼
